RegulatoryCompany release
FDA extends review of Belite Bio's tinlarebant for Stargardt disease to May 2027
Belite Bio, Inc (BLTE) · Fri 20 Nov 2026
The US regulator has pushed the action date for Belite Bio's Stargardt disease type 1 application back by three months, saying it needs more time to review supporting information.
Belite Bio announced on 20 November 2026 that the US Food and Drug Administration has extended the review of its new drug application for tinlarebant in Stargardt disease type 1. The Prescription Drug User Fee Act (PDUFA) action date moves back by three months to 12 May 2027.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Belite Bio, Inc ↗
Article written by VigiEye from the official source (Belite Bio, Inc). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
FDA publishes new and revised draft product-specific guidances on bioequivalence for generics
🇺🇸 FDA · Fri 20 Nov 2026
Dutch inspectorate posts Biotronik field safety notice on ICD and CRT-D lithium plating
🇳🇱 IGJ · Thu 19 Nov 2026
Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045
🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Thu 19 Nov 2026
China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia
HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026
FDA publishes Q&A guidance on transferring a 510(k) clearance between holders
🇺🇸 FDA CBER · Thu 19 Nov 2026